A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors

Pediatric Blood and Cancer

Volumn 60, Issue 2, 2013, Pages 230-236

  Macy, Margaret E ^a,b   Duncan, Tracey ^a,b   Whitlock, James ^c   Hunger, Stephen P ^a,b,d   Boklan, Jessica ^e   Narendren, Aru ^f   Herzog, Cynthia ^g   Arceci, Robert J ^h   Bagatell, Rochelle ⁱ   Trippett, Tanya ^j   Christians, Uwe ^a   Rolla, Katherine ^j   Ivy, S Percy ^k   Gore, Lia ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e PHOENIX CHILDREN'S HOSPITAL   (United States)

^f ALBERTA CHILDREN'S HOSPITAL   (Canada)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

5 fluorouracil; Chemotherapy; FOLFOX; Oxaliplatin; Pediatrics; Phase 1

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ARTICLE; BICARBONATE BLOOD LEVEL; BLEEDING; CANCER PATIENT; CHEST TIGHTNESS; CHILD; CHORDOMA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERANCE; DYSESTHESIA; DYSPNEA; EPENDYMOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEPATOBLASTOMA; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LIVER CELL CARCINOMA; LYMPHOEPITHELIOMA; MALE; MEDULLOBLASTOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OSTEOSARCOMA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PONTINE GLIOMA; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOID TUMOR; SARCOMA; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; TERATOMA; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 84871168221     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24278     Document Type: Article

References (37)

1. Page JD, Husain I, Sancar A, et al. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 1990; 29: 1016-1024.
2. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4-12.
3. Woynarowski JM, Chapman WG, Napier C, et al. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998; 54: 770-777.
4. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-1865.
5. Faivre S, Chan D, Salinas R, et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003; 66: 225-237.
6. Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1: 227-235.
7. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 2004; 350: 2343-2351.
8. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
9. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
10. Fouladi M, Blaney SM, Poussaint TY, et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: A pediatric brain tumor consortium study. Cancer 2006; 107: 2291-2297.
11. Geoerger B, Doz F, Gentet JC, et al. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol 2008; 26: 4394-4400.
12. McGregor LM, Spunt SL, Furman WL, et al. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: A children's oncology group study. Cancer 2009; 115: 1765-1775.
13. Spunt SL, Freeman BB III, Billups CA, et al. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J Clin Oncol 2007; 25: 2274-2280.
14. McGregor LM, Spunt SL, Santana VM, et al. Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer 2009; 115: 655-664.
15. Beaty O III, Berg S, Blaney S, et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 2010; 55: 440-445.
16. Assenat E, Desseigne F, Thezenas S, et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: A phase II trial. Oncologist 2011; 16: 1557-1564.
17. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28: 4697-4705.
18. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529.
19. Peeters M, Cohn A, Kohne CH, et al. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. Clin Colorectal Cancer 2012; 11: 14-23.
20. Saltz L, Badarinath S, Dakhil S, et al. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer 2012; 11: 101-111.
21. Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002; 87: 393-399.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
23. Erkmen K, Egorin MJ, Reyno LM, et al. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol 1995; 35: 254-256.
24. Rocci ML, Jr., Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983; 16: 203-216.
25. Gaynon PS. Carboplatin in pediatric malignancies. Semin Oncol 1994; 21: 65-76.
26. Kortmann RD, Kuhl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT'91. Int J Radiat Oncol Biol Phys 2000; 46: 269-279.
27. Ninane J, Perilongo G, Stalens JP, et al. Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: A SIOP pilot study. Med Pediatr Oncol 1991; 19: 199-203.
28. Pein F, Tournade MF, Zucker JM, et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms tumor-A phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994; 12: 931-936.
29. Uchida A, Myoui A, Araki N, et al. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer 1997; 79: 411-415.
30. van Hoff J, Grier HE, Douglass EC, et al. Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity. Cancer 1995; 75: 2966-2970.
31. Bastian G, Barrail A, Urien S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs 2003; 14: 817-824.
32. Delord JP, Umlil A, Guimbaud R, et al. Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol 2003; 51: 127-131.
33. Zaanan A, Flejou JF, Emile JF, et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 2011; 17: 7470-7478.
34. Des Guetz G, Lecaille C, Mariani P, et al. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. Anticancer Res 2010; 30: 4297-4301.
35. Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66: 659-667.
36. Chua W, Goldstein D, Lee CK, et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 2009; 101: 998-1004.
37. Wainberg ZA, Lin LS, DiCarlo B, et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011; 105: 760-765.